MiNA Therapeutics Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
MiNA Therapeutics is a biotechnology research company focused on restoring normal cellular function by activating genes through an innate mechanism. Its platform aims to enable new medicines that address severe liver diseases and other conditions by returning cells to a healthy state, working with partners to translate this approach into therapies. Based in London, England, the company operates within the biotechnology research sector and targets researchers and industry partners seeking novel treatments. In March 2025 MiNA announced leadership updates, including Bríd Ryan being appointed Chief Scientific Officer and Norbert Bischofberger joining the board as a Non-Executive Director. These changes reflect an emphasis on strengthening scientific leadership as the company advances its programs.